Isentress raltegravir: Additional Phase III data

Additional data from the 96-week, double-blind, international Phase III ONCEMRK trial in 797 treatment-naive patients with HIV-1 infection showed that a once-daily formulation of 1,200 mg Isentress (dosed as two 600 mg tablets) plus Truvada emtricitabine/tenofovir led to HIV-1 RNA levels of <40 copies/mL at week 48, the primary endpoint, in 88.9% of patients vs. 88.3% of patients receiving twice-daily 400 mg Isentress plus Truvada. Data were presented at the International AIDS Conference in Durban. Merck previously reported that the once-daily formulation of Isentress plus Truvada met the primary endpoint of non-inferiority to the twice-daily formulation of Isentress plus Truvada (see BioCentury, Feb. 29). ...